Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1).
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| GUTS | FRACTYL HEALTH, INC. | 2026-05-22 14:59:27 | 0.9 | 0 | -0.48 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GUTS | 0001572616 | FRACTYL HEALTH, INC. | US35168W1036 | — | 273553477 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 3 VAN DE GRAAFF DRIVE | BURLINGTON | MA | 01803 | UNITED STATES | US | 781-902-8800 | 3 VAN DE GRAAFF DRIVE, BURLINGTON, MA, 01803 | 3 VAN DE GRAAFF DRIVE, BURLINGTON, MA, 01803 | Fractyl Laboratories Inc. | Metabolic diseases | 2010 | Harith Rajagopalan | 88 | http://fractyl.com | 49,600,000 | 158,648,963 | 158,648,963 | Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1). | 2026-05-21 18:37:09 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 49,600,000 | -94,800,000 | -65.651 | 158,648,963 | 109,728,742 | 224.3014 |
| 2024 | 144,400,000 | 144,400,000 | 100 | 48,920,221 | 48,920,221 | 100 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Harith Rajagopalan | Chief Executive Officer | 2025 | 610,000 | — | — | 366,000 | 422 | 6,414,290 |
| Sarah Toomey | Corporate Secretary, General Counsel | 2025 | 445,000 | — | — | 193,000 | 648 | 2,445,850 |
| Jay D. Caplan | President, Chief Product Officer | 2025 | 475,000 | — | — | 190,000 | 1,858 | 3,043,034 |
| Jay D. Caplan | President, Chief Product Officer | 2024 | 468,077 | — | — | 142,500 | 600 | 2,198,612 |
| Lisa A. Davidson | Chief Financial Officer, Treasurer | 2024 | 445,385 | — | 0 | 135,000 | 600 | 1,972,272 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 100 |
| 2024 | 107 |
| 2023 | 102 |
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Revenue | 0 | 93,000 |
| Cost Of Revenue | 0 | 50,000 |
| Gross Profit | 0 | 43,000 |
| Research And Development Expenses | 74,536,000 | 70,471,000 |
| General And Administrative Expenses | 22,280,000 | 23,103,000 |
| Operating Expenses | 96,816,000 | 93,574,000 |
| Operating Income | -96,816,000 | -93,531,000 |
| Net Income | -140,954,000 | -68,694,000 |
| Earnings Per Share Basic | -1.86 | -1.62 |
| Earnings Per Share Diluted | -1.86 | -1.62 |
| Weighted Average Shares Outstanding Basic | 75,819,960 | 43,541,527 |
| Weighted Average Shares Outstanding Diluted | 75,819,960 | 43,541,527 |
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Cash And Cash Equivalents | 81,540,000 | 67,464,000 |
| Marketable Securities Current | — | — |
| Accounts Receivable | — | 0 |
| Inventories | — | 73,000 |
| Non Trade Receivables | — | — |
| Other Assets Current | — | — |
| Total Assets Current | 87,576,000 | 71,763,000 |
| Marketable Securities Non Current | — | — |
| Property Plant And Equipment | 2,407,000 | 2,979,000 |
| Other Assets Non Current | 337,000 | 666,000 |
| Total Assets Non Current | 33,826,000 | 36,314,000 |
| Total Assets | 121,402,000 | 108,077,000 |
| Accounts Payable | 1,574,000 | 3,240,000 |
| Deferred Revenue | — | — |
| Short Term Debt | — | — |
| Other Liabilities Current | — | — |
| Total Liabilities Current | 18,329,000 | 19,775,000 |
| Long Term Debt | — | 30,162,000 |
| Other Liabilities Non Current | 663,000 | 998,000 |
| Total Liabilities Non Current | 93,615,000 | 59,878,000 |
| Total Liabilities | 111,944,000 | 79,653,000 |
| Common Stock | 1,000 | 0 |
| Retained Earnings | -556,264,000 | -415,310,000 |
| Accumulated Other Comprehensive Income | — | — |
| Total Shareholders Equity | 9,458,000 | 28,424,000 |
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Depreciation And Amortization | 1,129,000 | 677,000 |
| Share Based Compensation Expense | 6,684,000 | 14,426,000 |
| Other Non Cash Income Expense | — | — |
| Change In Accounts Receivable | — | -22,000 |
| Change In Inventories | -73,000 | — |
| Change In Non Trade Receivables | — | — |
| Change In Other Assets | -2,248,000 | 2,197,000 |
| Change In Accounts Payable | -1,666,000 | 2,686,000 |
| Change In Other Liabilities | 414,000 | 5,654,000 |
| Cash From Operating Activities | -90,328,000 | -65,521,000 |
| Purchases Of Marketable Securities | — | — |
| Sales Of Marketable Securities | — | — |
| Acquisition Of Property Plant And Equipment | 557,000 | 1,765,000 |
| Acquisition Of Business | — | — |
| Other Investing Activities | — | — |
| Cash From Investing Activities | -557,000 | -1,765,000 |
| Tax Withholding For Share Based Compensation | — | — |
| Payments Of Dividends | — | — |
| Issuance Of Common Stock | 6,778,000 | 100,277,000 |
| Repurchase Of Common Stock | — | — |
| Issuance Of Long Term Debt | — | — |
| Repayment Of Long Term Debt | — | — |
| Other Financing Activities | — | — |
| Cash From Financing Activities | 104,961,000 | 101,226,000 |
| Change In Cash | 14,076,000 | 33,940,000 |
| Cash At End Of Period | 81,540,000 | 67,464,000 |
| Income Taxes Paid | — | — |
| Interest Paid | 4,300,000 | 3,127,000 |
| Fiscal Year | 2025 |
|---|---|
| Earnings Per Share | -1.86 |
| Price To Earnings Ratio | -1.1828 |
| Earnings Growth Rate | 14.8148 |
| Price Earnings To Growth Ratio | -0.0798 |
| Book Value Per Share | 0.1247 |
| Price To Book Ratio | 17.6363 |
| Ebitda | -139,825,000 |
| Enterprise Value | — |
| Dividend Yield | — |
| Dividend Payout Ratio | — |
| Debt To Equity Ratio | — |
| Capital Expenditures | 557,000 |
| Free Cash Flow | -90,885,000 |
| Return On Equity | -14.9032 |
| One Year Beta | 0.5236 |
| Three Year Beta | 0.9483 |
| Five Year Beta | 0.9483 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Smith Weber Lara | Chief Financial Officer | 2026-01-12 | 1,036,800 | A | 1,036,800 |
| Toomey Sarah | General Counsel | 2025-12-15 | 743,913 | A | 743,913 |
| Rajagopalan Harith | Director, Chief Executive Officer | 2025-12-15 | 2,486,302 | A | 2,486,302 |
| Caplan Jay David | President, Chief Product Off. | 2025-12-15 | 845,226 | A | 845,226 |
| Rajagopalan Harith | Director, Chief Executive Officer | 2025-12-04 | 10,416 | A | 501,745 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 2026-03-31 | 654,000 | 1,428,571 | 0.4578 |
| BANK OF AMERICA CORP /DE/ | 2026-03-31 | 57,120 | 124,989 | 0.457 |
| 683 Capital Management, LLC | 2026-03-31 | 3,079,728 | 6,727,235 | 0.4578 |
| BARCLAYS PLC | 2026-03-31 | 53,127 | 116,048 | 0.4578 |
| BOOTHBAY FUND MANAGEMENT, LLC | 2026-03-31 | 125,995 | 275,219 | 0.4578 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| BRIDGEWAY FUNDS INC | 2026-03-31 | Class N | BRSIX | 208,925 | 95,645.87 | 0.0778 |
| FIDELITY CONCORD STREET TRUST | 2026-02-28 | Fidelity Extended Market Index Fund | FSMAX | 527,317 | 247,469.87 | 0.0006 |
| FIDELITY CONCORD STREET TRUST | 2026-02-28 | Fidelity Nasdaq Composite Index Fund | FNCMX | 104,682 | 49,127.26 | 0.0002 |
| FIDELITY CONCORD STREET TRUST | 2026-02-28 | Fidelity Series Total Market Index Fund | FCFMX | 181,077 | 84,979.44 | 0.0001 |
| FIDELITY CONCORD STREET TRUST | 2026-02-28 | Fidelity Total Market Index Fund | FSKAX | 214,366 | 100,601.96 | 0.0001 |